エピソード

  • MRNA Today - Jul 15: Moderna Sees Slight Dip

    MRNA Today - Jul 15: Moderna Sees Slight Dip
    2026/07/15
    Hey there! It’s Joey here, your friendly stock buddy and longtime investor. Let's chat about Moderna today. It was a bit of a red day for MRNA, down about two-thirds of a percent. Not a huge drop, but still a dip.

    So, here’s what went down. The stock wasn't really vibing with the market today. It got smoked worse than the overall market averages. Volume was way lighter than usual too, which usually means folks are kinda sitting on their hands instead of jumping in. You know, that classic slow bleed vibe.

    Now, why did this happen? Well, it seems like there’s a mix of stuff going on. For one, the CDC isn’t publishing that report on COVID-19 vaccine effectiveness. That’s a big deal for a company like Moderna, which has been riding the vaccine wave. When news like that drops, it can make investors a bit jittery, and they start hitting that sell button fast.

    Also, there was some chatter about the Affordable Care Act subsidies set to expire soon. This could impact healthcare stocks, including Moderna, since it might affect how people access vaccines and treatments down the line.

    On a brighter note, there was some buzz about Moderna’s early-stage research on a Hantavirus vaccine. That’s exciting stuff! Investors love to hear about new projects, especially in the vaccine space. But, honestly, the excitement didn’t translate to the stock today.

    And just to throw something out there, Moderna’s been mentioned as one of the vaccine stocks to keep an eye on for 2026. That could mean potential upside in the future if they hit it big with new products.

    So, yeah, it was a bit of a bummer day for Moderna. But that’s how the market rolls sometimes. Remember, this is just for fun and info, not financial advice. Keep doing your thing, and I’ll catch you later!
    続きを読む 一部表示
    2 分
  • MRNA Today - Jul 14: Profit-Taking After Rally

    MRNA Today - Jul 14: Profit-Taking After Rally
    2026/07/14
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we’re talking about Moderna, MRNA for those in the know. It was a red day for them, barely moving, down just a smidge, about 0.21%.

    So, what happened? Well, Moderna got smoked today. After a solid rally last week, where it jumped up 20%, some folks decided it was time to take profits. You know how it goes, right? When things get hot, people start cashing in. Plus, there’s some chatter about this hantavirus buzz that’s got people talking, but it didn’t help the stock today.

    Now, why did the stock take this hit? A few reasons. For one, it seems like investors were getting a bit jittery after such a nice run-up. The market kinda had a rough day overall too, which didn’t help. Plus, there was news that the CDC won’t publish a report on COVID-19 vaccine effectiveness. That’s a big deal for Moderna, who’s been riding that vaccine wave. It’s like when your favorite show gets canceled—just leaves you feeling a little empty, ya know?

    Oh, and speaking of news, Moderna's working on a bird flu vaccine that’s hit late-stage testing. That’s something to keep an eye on. It could be a game-changer if it takes off.

    So, yeah, today was a bit of a bummer for Moderna. But hey, that’s the market for you—one day you’re up, the next you’re down. Just remember, this is all for fun and info, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • MRNA Today - Jul 13: Profit-Taking Hits Moderna

    MRNA Today - Jul 13: Profit-Taking Hits Moderna
    2026/07/13
    Hey there! It’s Joey, your friendly investor buddy here, breaking down what went down today with Moderna, ticker MRNA. Spoiler alert: it was a bit of a red day. The stock barely moved, closing down just a smidge at 0.53%.

    So, what happened? Well, it seems like people were hitting that sell button pretty fast today. After a solid 20% rally earlier this week, some investors decided to cash in their chips. You know how it goes; when you see a nice gain, it’s hard to resist taking a little profit. Plus, there was some chatter about the hantavirus that kinda added to the mix. Nothing like a little buzz to shake things up, right?

    Now, let’s talk about why this happened. There was a lot of buzz around Moderna’s flu vaccine decision, which is causing some folks to rethink its valuation. It’s like everyone is trying to figure out what this means for the stock in the long run. And if that wasn’t enough, Y Intercept Hong Kong Ltd sold off a hefty chunk of shares—around 444,000. That’s a big sell-off and definitely gets people talking.

    On top of all that, there’s been some chatter about Arbutus Biopharma validating their intellectual property claims against Moderna. That’s a whole other layer of drama that could impact investor sentiment. So yeah, it’s definitely a lot for people to chew on right now.

    One quick thing on the horizon: Moderna is still in the spotlight for its vaccine developments, and investors are keeping a close eye on how that plays out. It’s like a rollercoaster ride; you never really know what’s coming next, but you gotta hold on tight!

    So, in short, today was a bit of a profit-taking day for Moderna. If you’re holding shares, you might feel that little sting from the dip. Just remember, the stock market is always full of ups and downs. That’s just how it goes!

    Alright, folks, that’s a wrap for today’s recap. Just remember, this is all for info and entertainment—no financial advice here! Catch you later!
    続きを読む 一部表示
    2 分
  • MRNA Today - Jul 12: Biotech Sector Takes a Hit

    MRNA Today - Jul 12: Biotech Sector Takes a Hit
    2026/07/12
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we’re talking about Moderna. Spoiler: it was a red day for MRNA, dropping about 11%. Ouch!

    So, what went down? Moderna got smoked today, along with a bunch of other biotech stocks. It was like a domino effect in the sector. People were hitting that sell button hard, and it didn’t help that the overall market was shaky too. Volume was pretty high, but it still couldn't save the stock from this drop.

    Now, why did this happen? Well, it looks like there’s a broader biotech rout going on. Other companies like ImmunityBio and Sarepta Therapeutics also took a hit, down around 8% each. Investors seem to be getting jittery about the whole biotech scene lately, and Moderna just got swept up in the chaos. Also, there’s this settlement payout coming from Moderna, which might’ve added to the tension. It’s like everyone’s looking for a reason to panic, and today was that day for MRNA.

    Here’s a quick thing to keep in mind: Moderna’s had a rough week, and it's on track for its worst week in almost a year. That’s gotta sting for anyone holding the stock.

    So, to wrap it up, today was pretty brutal for Moderna and the biotech sector overall. Just remember, I’m here to keep you informed, not to give financial advice. So take this info and do what you will with it! Catch you later!
    続きを読む 一部表示
    1 分
  • MRNA Today - Jul 11: Biotech Stocks Take a Hit

    MRNA Today - Jul 11: Biotech Stocks Take a Hit
    2026/07/11
    Hey there! It’s Joey, your friendly neighborhood investor, and I’m here to break down what went down with Moderna today. So, let’s talk about MRNA. It was a rough day, and yeah, it got smoked, dropping about 10.83%—yikes!

    So, here’s the deal. Moderna opened up and just kept sliding. It was like watching a slow-motion train wreck. At one point, it hit a low of around 67 bucks, but it never really bounced back. People were definitely hitting the sell button fast, and you could feel the panic in the air.

    Why the drop? Well, it looks like Moderna wasn’t alone in this mess. The whole biotech sector took a beating today. Other companies like ImmunityBio and Sarepta Therapeutics also saw their stocks tumble, each dropping around 8%. It’s like a bad day for the whole crew. Some chatter out there suggests this might be a reaction to some shifting priorities at Moderna's board level. People are wondering if they’re changing how they allocate capital, which could be a big deal, but honestly, nobody really knows for sure what's cooking behind the scenes.

    One thing worth noting is that volume was pretty high today, with over 9 million shares traded. That’s above average and shows folks were definitely getting in on the action, even if it was mostly selling.

    So, yeah, it was a tough day for MRNA. If you’re watching this stock, keep an eye on those board changes and how they might affect the future. But remember, I’m just here sharing what’s happening, not giving any advice.

    Catch you later, and stay savvy out there!
    続きを読む 一部表示
    1 分
  • MRNA Today - Jul 10: Market Fluctuations Hit Hard

    MRNA Today - Jul 10: Market Fluctuations Hit Hard
    2026/07/10
    Hey there! It’s Joey, your friendly longtime investor here, breaking down today’s stock action. We’re talking about Moderna, and man, it was a rough day for them. The stock got smoked, dropping over 10%.

    So, here's the scoop. Moderna opened up today and looked like it might hang in there, but then it started slipping fast. By the end of the day, it was down big. Like, a real kick in the teeth for anyone holding shares.

    Now, why’d this happen? Well, there’s a couple of things going on. First off, it seems like the whole market vibe was a bit shaky today, and Moderna really felt that. Plus, Morgan Stanley dropped a neutral rating on the stock, even though they did bump up their price target. It’s like saying, “Hey, we think you can do better, but we’re not feeling super confident about you right now.” That one stung, and investors didn’t take it well. People were quick to hit that sell button, and the stock just kept sliding.

    On top of that, QRG Capital Management picked up a new stake in Moderna, which is usually good news. But in this case, it didn’t do much to lift the spirits. It’s like when you get a cool gift, but it’s not really what you wanted. Just a little too late to make a difference.

    One thing to keep an eye on is the overall market trends. If things stay rocky, it could keep dragging Moderna down with it. So, just something to think about as we move forward.

    Alright, that’s the lowdown for today. Remember, I’m just here to share what’s happening, not to give any financial advice. Stay informed, stay chill, and catch you later!
    続きを読む 一部表示
    1 分
  • MRNA Today - Jul 09: Morgan Stanley Neutral Rating

    MRNA Today - Jul 09: Morgan Stanley Neutral Rating
    2026/07/09
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today I’m breaking down what went down with Moderna, or MRNA. Spoiler alert: it was a red day for them, dropping about 3.5%. Oof.

    So, here’s the scoop. MRNA opened the day looking pretty decent, but then it got smoked after Morgan Stanley decided to stick with a neutral rating. Even though they lifted their price target, that didn’t really pump up the stock. People hit the sell button fast, and the shares took a dive. It’s like everyone just decided they weren’t feeling it anymore.

    Now, let’s talk about the why. Morgan Stanley’s move was kinda surprising to folks since there was some buzz around Moderna lately. They had that big six-day winning streak, right? But then, after appointing a new board member and retreating from a 52-week high, it seems investors got a little jittery. Plus, there’s that whole S&P 500 loser title they snagged today, which doesn't help the vibe. It’s like the stock is trying to find its footing, but the market’s just not having it right now.

    Looking ahead, Moderna’s got a results call coming up on July 31. That could be a big moment for them. Investors will be tuning in to see what’s next, especially after all the back and forth lately.

    Alright, that’s the rundown! Just remember, I’m here to keep you in the loop, not to tell you what to do with your cash. Keep it chill, and I’ll catch you later!
    続きを読む 一部表示
    1 分
  • MRNA Today - Jul 09: Morgan Stanley Neutral Rating

    MRNA Today - Jul 09: Morgan Stanley Neutral Rating
    2026/07/09
    Hey there! I’m Joey, your go-to guy for stock talk. I’ve been investing for years, and today, we’re chatting about Moderna, ticker MRNA. It was a bit of a mixed bag today, closing up about 3.5%.

    So, what happened? Well, it started strong but then kind of fizzled out. Moderna hit a high earlier this week but then took a hit after some news came through. People were feeling optimistic—like, it had a nice little run recently. But then Morgan Stanley decided to stick with a neutral rating on the stock. Yeah, that one stung a bit, especially since they did raise their price target but didn’t give it a glowing review.

    Now, why did investors seem to hit the sell button? It looks like there’s a bit of a disconnect between the price target bump and the neutral stance. Some folks were hoping for a more bullish take, especially after that recent surge of 37% over six days. It seems like the market was kinda like, "Well, if they’re not super excited, why should we be?" That led to some selling pressure, and the stock dipped from its recent highs.

    On the flip side, there’s still some good stuff happening. Moderna’s got a corporate update scheduled for July 31. They’re planning to share some results, and who knows? That could shake things up again.

    So, to wrap it all up, Moderna had a decent day, but the Morgan Stanley news definitely brought it down from those highs. Always a bit of a rollercoaster, right? Just remember, I’m here to keep you in the loop for fun and info, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分